← All trials
NCT06006702
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 16, 2023
- Primary completion
- Jan 31, 2024
- Completion date
- Jul 31, 2024
- First posted
- Aug 23, 2023
- Last posted
- Nov 15, 2023
- Enrollment
- 36
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tyra Biosciences, IncLead sponsor
- Tyra Biosciences, IncStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.